免疫检查点抑制剂的心脏毒性及其机制

被引：10

作者：

董爽

胡胜

欧武陵

蔡茜

机构：

[1] 湖北省肿瘤医院胸部肿瘤内科一病区

来源：

肿瘤防治研究 | 2018年 / 45卷 / 11期

关键词：

免疫治疗; 不良反应; 心脏毒性;

D O I：

暂无

中图分类号：

R730.51 [免疫疗法];

学科分类号：

100108 [医学免疫学];

摘要：

免疫检查点抑制剂(immune checkpoint inhibitor, ICI)的发展,推动了癌症治疗的革命性变化。ICI通过细胞免疫表面检查点(immune checkpoint)蛋白刺激免疫系统识别和破坏癌细胞。然而,使用ICI还可能在靶外器官(如心脏)中诱导免疫相关的不良事件(immune-related adverse events,irAE)。心脏损害的最常见表现是心肌炎,尽管罕见,但这些脱靶效应却可能危及生命。现有数据表明,ICI通过几种机制诱导其脱靶效应,包括直接结合正常组织中表达的细胞表面蛋白、激活与脱靶组织交叉反应的T细胞、产生自身抗体或增加前炎性细胞因子的水平。更好地了解癌症免疫治疗的不利影响及其潜在机制,将有助于开发生物标志,以识别有风险的患者和预防这些irAE的方法。

引用

页码：858 / 863

页数：6

共 12 条

[1]

运用抗PD-L1抗体治疗晚期癌症患者的安全性与疗效评价 [J].

姜孝新 ;

Julie R.Brahmer ;

Scott S.Tykodi ;

Laura Q.M.Chow .

肿瘤药学, 2012, 2 (03) :240

[2]

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors [J].

Mahmood, Syed S. ;

Fradley, Michael G. ;

Cohen, Justine V. ;

Nohria, Anju ;

Reynolds, Kerry L. ;

Heinzerling, Lucie M. ;

Sullivan, Ryan J. ;

Damrongwatanasuk, Rongras ;

Chen, Carol L. ;

Gupta, Dipti ;

Kirchberger, Michael C. ;

Awadalla, Magid ;

Hassan, Malek Z. O. ;

Moslehi, Javid J. ;

Shah, Sachin P. ;

Ganatra, Sarju ;

Thavendiranathan, Paaladinesh ;

Lawrence, Donald P. ;

Groarke, John D. ;

Neilan, Tomas G. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (16) :1755-1764

[3]

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis [J].

Moslehi, Javid J. ;

Salem, Joe-Elie ;

Sosman, Jeffrey A. ;

Lebrun-Vignes, Benedicte ;

Johnson, Douglas B. .

LANCET, 2018, 391 (10124) :933-933

[4]

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review [J].

Khoja, L. ;

Day, D. ;

Chen, T. Wei-Wu ;

Siu, L. L. ;

Hansen, A. R. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2377-2385

[5]

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer [J].

Yearley, Jennifer H. ;

Gibson, Christopher ;

Yu, Ni ;

Moon, Christina ;

Murphy, Erin ;

Juco, Jonathan ;

Lunceford, Jared ;

Cheng, Jonathan ;

Chow, Laura Q. M. ;

Seiwert, Tanguy Y. ;

Handa, Masahisa ;

Tomassini, Joanne E. ;

McClanahan, Terrill .

CLINICAL CANCER RESEARCH, 2017, 23 (12) :3158-3167

[6]

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer [J].

Osorio, J. C. ;

Ni, A. ;

Chaft, J. E. ;

Pollina, R. ;

Kasler, M. K. ;

Stephens, D. ;

Rodriguez, C. ;

Cambridge, L. ;

Rizvi, H. ;

Wolchok, J. D. ;

Merghoub, T. ;

Rudin, C. M. ;

Fish, S. ;

Hellmann, M. D. .

ANNALS OF ONCOLOGY, 2017, 28 (03) :583-589

[7]

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma [J].

Tarhini, Ahmad A. ;

Zahoor, Haris ;

Lin, Yan ;

Malhotra, Usha ;

Sander, Cindy ;

Butterfield, Lisa H. ;

Kirkwood, John M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

[8]

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome [J].

Geisler, Benjamin P. ;

Raad, Roy A. ;

Esaian, Diana ;

Sharon, Elad ;

Schwartz, David R. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

[9]

Human CD14<sup>+</sup>CTLA‐4<sup>+</sup> regulatory dendritic cells suppress T‐cell response by cytotoxic T‐lymphocyte antigen‐4‐dependent IL‐10 and indoleamine‐2;3‐dioxygenase production in hepatocellular carcinoma.[J].Yanmei Han;Zhubo Chen;Yuan Yang;Zhengping Jiang;Yan Gu;Yangfang Liu;Chuan Lin;Zeya Pan;Yizhi Yu;Minghong Jiang;Weiping Zhou;Xuetao Cao.Hepatology.2014, 2

[10]

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

← 1 2 →